Traitement symptomatique de l'occlusion intestinale sur carcinose péritonéale : Recommandations de bonnes pratiques cliniques
Guillemette Laval(Université Grenoble Alpes), Éric Terrebonne(Hôpital Cardiologique du Haut-Lévêque), Blandine Marcelin-Benazech(Hospices Civils de Lyon), Éric François(Centre Antoine Lacassagne), Christine Rebischung, Frédéric Guirimand, L. Chauvenet(Assistance Publique – Hôpitaux de Paris), Aurélie Durand(Centre National de la Recherche Scientifique), C. Arvieux(Centre Hospitalier Universitaire de Grenoble), Martine Gabolde(Hôpital Paul-Brousse), Vincent Servois(Institut Curie), Laure Copel(Institut Curie), Pascale Mariani(Institut Curie)
Cited by 6
Related Papers
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
|Journal of Clinical Oncology|2012|431
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|JAMA Oncology|2022|322